Commercial Breeding for Laboratories

Debate between Sarah Dines and Emma Hardy

Monday 16th January 2023 Westminster Hall

[The Parliamentary Under-Secretary of State for the Home Department (Miss Sarah Dines)]

It is a pleasure to appear under your chairmanship, Mr Efford. I thank my hon. Friend the Member for Carshalton and Wallington (Elliot Colburn) for introducing today’s debate, and I thank all other colleagues for their valuable interventions and contributions.

The Government recognise that this is a policy issue of huge importance and high public interest. It is therefore right and proper that there is scrutiny of the matters that we have discussed today. In opening, I would like to clarify the Government’s position on the use of animals in science and make some overall comments on progress in this area.

We all benefit from the use of animals in science. That can be through improved knowledge of how tissues and organs work to help find new treatments for disease and illness; the development and safety testing of medicines before they are trialled and then used in humans; the safety testing of chemicals to protect workers and the environment; veterinary research and medicines to support animal health; and the protection of the natural environment and the preservation of species. When we need medical care, we benefit from medicines and medical technologies that are possible due to knowledge gained from the use of animals in research. We trust those medicines are safe to use because of the rigorous testing requirements, including at times the use of animals.

[Emma Hardy]

There seem to be an awful lot of presumptions in the opening of the Minister’s speech, including presumption that we all benefit from testing on animals, despite the evidence that many Members have provided. I gave two examples, including a case where animals were used for testing, but when a dose 500 times lower was used on humans, it killed five. I ask the Minister to re-evaluate the assumption that humans always benefit from the testing of products on animals.

--- Later in debate ---

[Miss Dines]

I will make some progress first. Our approach has two fronts. First, robust regulation will ensure that animals are not used where a non-animal alternative could deliver the benefit sought, and secondly, our strategic aim is to facilitate and promote alternatives to animals in scientific research and testing. I therefore believe that we have a shared aim of fully replacing live animals as soon as possible, where that is safe and scientifically possible.

A number of Departments have a stake in the use of animals in science, including: the Department for Business, Energy and Industrial Strategy, which leads on science, research and innovation, including alternatives to the use of animals; the Department of Health and Social Care, which is responsible for the regulation of medicines; and the Department for Environment, Food and Rural Affairs, which is responsible for chemical safety and veterinary medicine regulations. The Home Office does not require or commission the use of animals in science. Instead, we regulate to ensure that all proposals for work are authorised only where there is justified benefit, that animals are used only where there is no alternative, that the minimum number of animals is used, that harm is minimised, and that the animals are appropriately cared for. I reject the narrative suggesting that that is not the case. My colleague Lord Sharpe has ministerial responsibility for this work.

By way of background, the debate on animals in scientific research has at its centre three critical strategic imperatives: first, the delivery of the benefits of the use of animals in scientific research; secondly, the delivery of a rigorous and robust regulatory system; and thirdly, the development of alternatives to the use of live animals in procedures. Taken together, these imperatives drive the Government’s policy on the use of animals in science. I will focus my comments on the issues raised by Members in this interesting debate.

[Emma Hardy]

Will the Minister give way?

[Miss Dines]

I will make a little more progress, and then I will, of course, come back. The issues raised include the use of animals in science and its regulation, the commercial breeding of laboratory animals, and the development, promotion and acceptance of non-animal methodologies. To be clear, as was said, the UK has never set out to use animals in science. Instead, we have set out to deliver public safety, world-class health innovations and breakthroughs, and to make life-changing discoveries, from new vaccines and medicines to transplant procedures, anaesthetics and blood transfusions. Indeed, the development of the covid-19 vaccine was possible because of the use of animals in research. The use of animals in science must always be considered in the broader context. Animal research and testing is only ever a small part of a wider programme.